Document is current
Any future updates will be listed below
-
Authors
Schlepckow, Kai
Monroe, Kathryn M
Kleinberger, Gernot https://orcid.org/0000-0002-5811-8226
Cantuti‐Castelvetri, Ludovico
Parhizkar, Samira
Xia, Dan
Willem, Michael
Werner, Georg
Pettkus, Nadine
Brunner, Bettina
Sülzen, Alice
Nuscher, Brigitte
Hampel, Heike
Xiang, Xianyuan
Feederle, Regina https://orcid.org/0000-0002-3981-367X
Tahirovic, Sabina https://orcid.org/0000-0003-4403-9559
Park, Joshua I
Prorok, Rachel
Mahon, Cathal
Liang, Chun‐Chi
Shi, Ju
Kim, Do Jin
Sabelström, Hanna
Huang, Fen
Di Paolo, Gilbert
Simons, Mikael
Lewcock, Joseph W https://orcid.org/0000-0003-3012-7881
Haass, Christian https://orcid.org/0000-0002-4869-1627
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (EXC 2145; ID 390857198 SyNergy)
Deutsche Forschungsgemeinschaft (HA1737/16‐1)
Helmholtz Association (ZT‐0027)
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Innovative Medicines Initiative (115976)
- License Information
-
More Information
Article History
Received: 30 July 2019
Revised: 12 February 2020
Accepted: 17 February 2020
First Online: 10 March 2020
Conflict of interest
: C.H. collaborates with Denali Therapeutics, participated on one advisory board meeting of Biogen, and received a speaker honorarium from Novartis and Roche. C.H. is chief advisor of ISAR Bioscience. J.W.L., K.M.M., J.I.P., H.S., J.S., R.P., D.X., C.M., D.J.K., C.C.L., F.H., and G.D.P. are employees of Denali Therapeutics.
